Table 3B.
Clinical trials of CD40 antagonist therapy
| Drug | Feature | Phase | Disease | Outcome | PMID/Identifier |
|---|---|---|---|---|---|
| Ch5D12 | Chimeric mAb | 1/2a | Crohn’s disease | Safe; Effective | 16011669 |
| Bleselumab | Human mAb | 1 | Moderate-severe psoriasis | Safe; Not effective | 29679478 |
| 1b, 2 | Kidney Transplantation | Safe; Noninferiority | 31509331 31397943 |
||
| BI 655064 | Humanized mAb | I | Healthy subject | Safe | 29127458 30113724 |
| 2a | Rheumatoid arthritis | Safe; Not effective | 30902820 | ||
| Iscalimab | Human mAb | 1 | Rheumatoid arthritis Healthy subject | Safe | 31647605 |
| 2 | Grave’s disease | Safe; Effective | 31512728 | ||
| 1/2 | Kidney Transplantation | Unpublished | NCT02217410 | ||
| 2 | Kidney transplantation Liver transplantation | Ongoing |
NCT03663335 NCT03781414 |
||
| 2 | Lupus nephritis | Ongoing | NCT03610516 | ||
| 2 | Systemic lupus erythematosus | Ongoing | NCT03656562 | ||
| 2 | Sjögren syndrome | Ongoing | NCT03905525 | ||
| Lucatumumab | Human mAb | 1 | CLL | Safe; Minimal efficiency | 22475052 |
| 1 | Relapsed MM | Safe; Moderate efficiency | 22861192 | ||
| 1a/2 | Advanced lymphoma | Safe; Moderate efficiency | 24219359 |
Abbreviations: CLL, chronic lymphocytic leukemia; mAb: monoclonal antibody; MM, multiple myeloma.